EUVIMEDEUVIMED entdecken
Crossref

Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy

Ivana Šušak Sporiš, Nada Božina, Iva Klarica Domjanović, Davor Sporiš, Silvio Bašić, Ivana Bašić, Mila Lovrić, Lana Ganoci, Vladimir Trkulja iD

Fundamental & Clinical Pharmacology · 2024-04 · 38 (2) · 351-368

DOI: 10.1111/fcp.12958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 04.10.2023. Verfasst von Ivana Šušak Sporiš und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Dubrava, Zagreb, Croatia. Hauptthemen laut MEDLINE: Epilepsy, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Valproate inhibits clearance of lamotrigine and greatly increases its concentrations. We assessed whether this effect was moderated by a polymorphism ( ABCG2 c.421C>A ) of the breast cancer resistance protein.

Methods

In two consecutive independent studies in adults with epilepsy on lamotrigine monotherapy or cotreated with valproate: (i) Exposure to valproate was considered treatment, (ii) dose‐adjusted lamotrigine troughs at steady state were the outcome, and (iii) ABCG2 c.421C>A genotype (wild‐type [wt] homozygosity or variant carriage) was the tested moderator. We used entropy balancing (primary analysis) and exact/optimal full matching (secondary analysis) to control for confounding, including polymorphisms (and linked polymorphisms) suggested to affect exposure to lamotrigine ( UGT1A4*3 c.142T>G , rs2011425; UGT2B7–161C>T , rs7668258; ABCB1 1236C>T , rs1128503) to generate frequentist and Bayesian estimates of valproate effects (geometric means ratios [GMR]).

Results

The two studies yielded consistent results (replicated); hence, we analyzed combined data (total N = 471, 140 treated, 331 controls, 378 ABCG2 c.421C>A wt subjects, 93 variant carriers). Primary analysis: in variant carriers, valproate effect (GMR) on lamotrigine (treated, n = 21 vs. controls, n = 72) was around 60% higher than in wt subjects (treated, n = 119 vs. controls, n = 259)—ratio of GMRs 1.61 (95%CI 1.23–2.11) (frequentist) and 1.63 (95%CrI 1.26–2.10) (Bayes). Similar differences in valproate effects between variant carriers and wt subjects were found in the secondary analysis (valproate troughs up to 364 μmol/L vs. no valproate; or valproate ≥364 μmol/L vs. no valproate). Susceptibility of the estimates to unmeasured confounding was low.

Conclusion

Data suggest that polymorphism rs2231142 moderates the effect of valproate on exposure to lamotrigine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyBreast NeoplasmsAdultHumansFemaleValproic AcidLamotrigineBayes TheoremATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsAnticonvulsantsPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

ABCG2 c.421C>Abioavailabilitybreast cancer resistance proteinlamotriginevalproate

Substanzen

Valproic AcidLamotrigineATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsAnticonvulsantsABCG2 protein, human

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Dubrava, Zagreb, Croatia.
  • Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
  • Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia.
  • Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia.
  • Analytical Toxicology and Pharmacology Division, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
  • Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.

ORCID-Profile: Vladimir Trkulja

Zitieren

APA

Šušak Sporiš, I., Božina, N., Klarica Domjanović, I., Sporiš, D., Bašić, S., Bašić, I., Lovrić, M., Ganoci, L., & Trkulja, V. (2024). Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy. Fundamental & Clinical Pharmacology, 38(2), 351-368. https://doi.org/10.1111/fcp.12958

Vancouver

Šušak Sporiš I, Božina N, Klarica Domjanović I, Sporiš D, Bašić S, Bašić I, et al. Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy. Fundamental & Clinical Pharmacology. 2024;38(2):351-368. doi:10.1111/fcp.12958

BibTeX
@article{uakSpori2024,
  author = {Šušak Sporiš, Ivana and Božina, Nada and Klarica Domjanović, Iva and Sporiš, Davor and Bašić, Silvio and Bašić, Ivana and Lovrić, Mila and Ganoci, Lana and Trkulja, Vladimir},
  title = {Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  volume = {38},
  number = {2},
  pages = {351--368},
  doi = {10.1111/fcp.12958}
}
Kostenlos starten →